Written by PX1 Research Team
PX1 chemists and research educators with hands-on experience in US-based peptide manufacturing, HPLC / mass-spectrometry lot testing, and endotoxin QC. All content is citation-backed and peer-reviewed for accuracy.
CJC-1295 + Ipamorelin: The Most Studied GH Secretagogue Pairing
Research Guide
Reviewed By
PX1 QC — Analytical Chemistry Team
Every article is reviewed by PX1's in-house analytical team for accuracy on mechanism, dosing ranges reported in the literature, and lab-handling guidance. We do not publish clinical or medical advice.
Quick answer
Why researchers pair the GHRH analog CJC-1295 (no DAC) with the selective GHRP ipamorelin: complementary mechanisms, pulsatile GH release, study design, and handling.
Key takeaways
- CJC-1295 with DAC (Drug Affinity Complex) binds serum albumin, extending half-life to roughly a week — producing *sustained, non-pulsatile* GH elevation
- CJC-1295 without DAC (also called Mod GRF 1-29, a tetrasubstituted GHRH(1-29) analog) has a short half-life (~30 minutes) and preserves the body's pulsatile GH rhythm
- GHRH(1-29) analogs have been studied since the 1980s; Mod GRF 1-29's four substitutions were designed to resist DPP-4 cleavage and extend activity from minutes to ~30 minutes
- Combined GHRH + GHRP administration in human studies produced synergistic GH release — larger than the sum of either peptide alone
Why researchers pair these two compounds
Growth hormone release is governed by two complementary signals:
- GHRH (growth hormone releasing hormone) — tells the pituitary somatotroph cells to release GH
- Ghrelin / GHRP signal — amplifies the pulse and inhibits somatostatin (the "brake" on GH release)
CJC-1295 (no DAC) is a GHRH analog. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist. Because they act on different receptors controlling the same pulse, combining them produces a larger GH pulse than either alone — a synergy documented in the GHRH/GHRP literature since the 1990s. This is why the pairing is the most commonly referenced secretagogue combination in GH-axis research.
CJC-1295: with DAC vs without DAC
The distinction matters and is frequently confused:
- CJC-1295 with DAC (Drug Affinity Complex) binds serum albumin, extending half-life to roughly a week — producing sustained, non-pulsatile GH elevation
- CJC-1295 without DAC (also called Mod GRF 1-29, a tetrasubstituted GHRH(1-29) analog) has a short half-life (~30 minutes) and preserves the body's pulsatile GH rhythm
Most modern research designs use the no-DAC form, because physiological GH release is pulsatile and sustained elevation raises concerns about receptor desensitization in long-running studies.
What each compound contributes
| Compound | Receptor | Role in the pairing |
|---|---|---|
| CJC-1295 (no DAC) | GHRH receptor | Initiates the GH pulse |
| Ipamorelin | GHS-R1a (ghrelin receptor) | Amplifies the pulse; suppresses somatostatin |
Ipamorelin is typically chosen over GHRP-2 or GHRP-6 for this pairing because of its selectivity — GH release without the cortisol and prolactin elevations of the older peptides (see the standalone ipamorelin guide).
Published research context
- GHRH(1-29) analogs have been studied since the 1980s; Mod GRF 1-29's four substitutions were designed to resist DPP-4 cleavage and extend activity from minutes to ~30 minutes
- Combined GHRH + GHRP administration in human studies produced synergistic GH release — larger than the sum of either peptide alone
- Early clinical work on CJC-1295 (with DAC) showed dose-dependent GH and IGF-1 increases in healthy adults; the no-DAC form has been studied less formally but is the standard in contemporary preclinical designs
Laboratory handling
Both compounds ship lyophilized and are stable at -20°C sealed. For blend research, researchers typically reconstitute each vial separately with bacteriostatic water (or use a pre-mixed lyophilized blend from a single documented lot), refrigerate at 2–8°C, and use within a few weeks. Never mix reconstituted solutions from different lots in the same container.
Purity considerations
For a two-compound blend, verification means one COA per component or a blend COA that quantifies both peptides individually — HPLC ≥99% with visible chromatograms and mass-spec identity for each. A blend reported as a single purity number without per-compound data is not adequately documented.
Research use only. Neither compound is approved for human use; all applications are investigational.